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INTRODUCTION  
Currently different countries have to follow different 
regulatory requirements for approval of new drug. For 
marketing authorization application (MAA) a single 
regulatory approach is applicable to various countries is 
almost a difficult task. Therefore it is necessary to have 
knowledge about regulatory requirement for MAA of each 
country. 
The new drug approval process consists of two stages 
(phases)- the first phase is for clinical trials and second 
phase is for marketing authorization of drug. Firstly, non-
clinical studies of drug are completed to ensure safety and 
efficacy. The next step is the submission of application for 
conduction of clinical trials to competent authority of 
respected country. In next step, clinical trials are carried 
out in four phases i.e. phase 1 – phase 4 study. These 
studies are carried out for the assurance of safety, efficacy 
and for optimization of dose of drug in human being. Then 
application for marketing of drug is carried out by 
competent authorities.The competent authority review the 
application and approve the drug for marketing purpose, 
only if that drug found to be safe and effective with desired 
effect as compare to adverse effect. 
The following table indicates about the group of agencies 
working for drug approval procedure in their respected 
countries.
 
     NAME OF COUNTRY  AGENCIES FOR  DRUG REGULATION   
   USA    Centers for Disease Control and Prevention  
  Department of Health and Human Services (DHHS)  
  Fed World - US Government Information  
  The Food and Drug Administration (FDA)  
  National Center for Complementary and Alternative Medicine (NCCAM)  
  National Institutes of Health (NIH)  
  National Library of Medicine  
  National Science Foundation  
  Office of Disease Prevention  
   EUROPE   EU Legislation - Eudralex  
  European Directorate for the Quality of Medicines and Healthcare (EDQM)  
  European Medicines Agency (EMEA)  
  Heads of Medicines Agencies (HMA)  
   INDIA   Central Drug Standard Control Organization (CDSCO)  
  Government of India Directory of Health and Family Welfare  
  Indian Council of Medical Research (ICMR)  
  Ministry of Health and Family Welfare  
  CHINA  State Food and Drug Administration (SFDA)  
  AUSTRALIA • Australia's Department of Health and Aged Care  
•   Therapeutic Goods Administration (TGA)  
 
 
 
ABSTRACT  
Developing a new drug requires great amount of research work in chemistry, manufacturing, controls, preclinical science and 
clinical trials. Drug reviewers in regulatory agencies around the world bear the responsibility of evaluating whether the 
research data support the safety, effectiveness and quality control of a new drug product to serve the public health.Every 
country has its own regulatory authority, which is responsible to enforce the rules and regulations and issue the guidelines to 
regulate the marketing of the drugs. This article focuses on history, regulatory policy and administration, and related issues 
with respect to different countries like U.S.A. , Europe ,China, Australia  and India  
Keywords: USFDA, EMA, TGA, Clinical trials, Approval stages 
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USA: 
U.S. Pharmacopoeia was established in 1820 and Congress 
passed the original Food and drugs act, and signed by 
President Theodore Roosevelt. The Food and Drugs Act 
prohibits interstate 
Commerce in misbranded and adulterated foods, drinks, 
and drugs.  But in 1937, sulfanilamide tragedy occurred 
and due to which Federal Food, Drug and Cosmetic act 
was introduced and added new provisions including 
compulsion of showing safety of drug before its marketing. 
In 1962, The Kefauver- Harris Amendment Act was 
passed which require that manufacturers must prove that 
drug is safe and effective. Separate centers within the FDA 
regulate drugs, biologics, devices, and food.  
 
An investigational new drug application (IND) outlines 
what the sponsor of a new drug proposes for human testing 
in clinical trials Phase 1 studies (typically involve 20-80 
people) Phase 2 studies (typically involve a few dozen to 
about 300 people) . Phase 3 studies (typically involve 
several hundred to about 3,000 people) . The pre-NDA 
period, just before a new 
drug application (NDA) is submitted, is a common time 
for the FDA and drug sponsors to meet Submission of an 
NDA is the formal step the FDA takes to consider a drug 
for marketing approval 8. After an NDA is received, the 
FDA has 60 days to decide whether to file it so it can be 
reviewed 9. If the FDA files the NDA, an FDA review 
team is assigned to evaluate the sponsor’s research on the 
drug’s safety and effectiveness.  The FDA reviews 
information that 
goes on a drug’s professional labeling (information on how 
to use the drug) 11. The FDA inspects the facilities where 
the drug will be manufactured as part of the approval 
process . FDA reviewers will approve the application or 
find it either “approvable” or “not approvable” 
Preclinical - 
 Computer simulations, experimental animal studies,or in 
vitro studies are performed to 
 identify a promising drug 
 test for promising biologic effects 
 test for adverse effects 
 A drug company may test many related compounds to 
identify 1 or 2 to take further in development. The FDA is 
not involved in this aspect of drug development but will 
review the study results for any compounds that are 
planned for clinical (human) testing. 
New Drug Application (IND) 
 The IND – is the formal process by which a sponsor 
requests approval for testing of a drug in humans– includes 
information developed during preclinical testing regarding 
safety and effectiveness • Includes an “investigator 
brochure” that ensures that clinicians conducting the trial 
and their institutional review boards (IRBs) are adequately 
informed about possible effects of the drug. 
There are 3 phases in clinical testing of a new drug 
Phase 1 
Phase 1 studies are usually conducted in healthy 
volunteers. The emphasis in Phase 1 is on safety. The goal 
is– to determine what the drug's most frequent side effects 
areoften, to determine how the drug is absorbed, 
distributed, and excreted. The number of subjects typically 
ranges from 20 to 80. 
Phase 2 
 The emphasis in Phase 2 is on effectiveness. 
 The goal of a Phase 2 study is to obtain preliminary data 
on whether the drug works in people who have a specific 
disease or condition• For controlled trials, patients 
receiving the drug are compared with similar patients 
receiving a placebo or a different drug • Safety continues 
to be evaluated and short-term side effects are studied.  
Typically, the number of subjects in Phase 2 studies ranges 
from a few dozen to about 300 after Phase 2. 
 At the end of Phase 2, the FDA and sponsors negotiate 
about how the large-scale studies in Phase3 should be done 
. The FDA usually meets with a sponsor several times, 
including prior to Phase 3 studies, and pre-NDA right 
before a new drug application is submitted. 
Phase 3 
 Phase 3 studies begin if evidence of effectiveness is 
shown in Phase 2. Phase 3 studies  are usually placebo-
controlled – gather more information about safety and 
effectiveness – may test different dosages – may test the 
drug in different populations – usually include several 
hundred to about 3000 subjects – are often multi-center 
trials 
 
Clinical trials 
 Clinical trials compare the new drug to a placebo or to an 
existing therapy• The standard for effectiveness may be 
statistical superiority to placebo or non-inferiority to an 
existing therapy• Adverse events are recorded, because 
trial populations are relatively small, only the most 
common adverse events may be discovered – also, clinical 
trial populations are healthier than real-world populations--
for example, a trial of an anti-depressant may exclude 
subjects with substance use disorder 
The New Drug 
The NDA – is the formal request by a sponsor to market a 
drug in the U.S. – includes the results of preclinical and 
clinical studies, manufacturing information, and labeling – 
can be hundreds of thousands of pages. The FDA has 60 
days to decide whether to review the NDA 
 After deciding that it will review an NDA, the FDA has 
10 months to make a determination (6 months for priority 
drugs) Application (NDA). 
NDA Decisions 
Post marketing (Phase IV) Studies 
 As part of the approval process, the FDA may obtain 
commitments from the sponsor to do 
additional Phase 4 studies after the product is marketed. 
However, the FDA cannot enforce compliance. The FDA 
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also monitors adverse events through an adverse event 
surveillance program. 
Europe - 
 A sponsor has several options when seeking approval to 
market a new drug in Europe: a national authorization 
procedure, a decentralized procedure, a mutual recognition 
procedure, or a centralized procedure. Products that must 
use the centralized procedure include the following:  
 all biologic agents or other products made using high-
technology procedures 
 products for HIV/AIDS, cancer, diabetes, 
neurodegenerative diseases, auto-immune and other 
immune dysfunctions and viral diseases 
 products for orphan conditions 
National authorization procedure 
Each country within the EU has its own procedures for 
authorizing a marketing application for a new drug. A 
sponsor can consult the website of the regulatory agency in 
each country in which it is interested in obtaining 
marketing approval to obtain details of the approval 
process.A sponsor can also seek approval of several EU 
countries simultaneously using the decentralized or mutual 
recognition procedure. 
Decentralized procedure 
For products that fall outside the scope of the European 
Medicines Agency (EMA ) with regard to centralized 
procedures, a sponsor can submit under the decentralized 
procedure. Using this process, a sponsor can apply for 
simultaneous authorization in more than one EU country 
for products that have not yet been authorized in any EU 
country. 
Mutual recognition procedure. With the mutual recognition 
procedure, a product is first authorized by one country in 
the EU in accordance with the national procedures of that 
country. Later, further marketing authorizations can be 
sought from other EU countries, who, rather than 
conducting their own review, agree to recognize the 
decision of the first country. 
Centralized procedure 
European drug approvals are overseen by the European 
Medicines Agency. The EMA is a decentralized body of 
the EU, with headquarters in London, England. It is 
responsible for the scientific evaluation of applications for 
authorization to market medicinal products in Europe (via 
the centralized procedure).  Marketing applications for 
drugs for use in humans are evaluated by the Committee 
for Medicinal Products for Human Use (CHMP). 
Products that are eligible for review under the centralized 
procedure must meet the following criteria: 
 biologic drugs developed by recombinant technology, 
controlled expression of genes coding for biologically 
active proteins in prokaryotes and eukaryotes 
including transformed mammalian cells, and 
hybridoma and monoclonal antibody methods 
 medicinal products containing new active substances 
for the following indications: AIDS, cancer, 
neurodegenerative disorders, diabetes, autoimmune 
diseases and other immune dysfunctions, and viral 
diseases 
 orphan medicinal products 
Other new active substances may, at the request of the 
applicant, be accepted for consideration under the 
centralized procedure when it can be shown that the 
product constitutes a significant therapeutic, scientific or 
technical innovation, or the granting of a Community 
authorization is in the best interests of patients at the 
Community level. 
Pre-submission process 
At least seven months prior to submitting a marketing 
authorization application (MAA), a sponsor must notify 
the EMA of their intention to submit and the month of 
submission. This pre-submission involves a variety of 
information including a document outlining the reasons the 
sponsor believes the application should fall under the 
centralized procedure. The EMA will consider the pre-
submission and notify the sponsor of its decision regarding 
acceptance of the MAA.  
Selection of rapporteur/co-rapporteur - 
The rapporteur is a country-specific regulatory authority 
within the EU. The rapporteur (reviewer) and co-
rapporteur (if needed) are identified from the CHMP 
members. The selection of the rapporteur is based on 
objective criteria, to ensure objective scientific opinion and 
the best use of available expertise at the EMA. The role of 
the rapporteur is to perform the scientific evaluation and 
prepare an assessment report to the CHMP. If a co-
rapporteur is involved, the co-rapporteur will prepare an 
independent assessment report, or provide a critique of the 
rapporteur’s report, at the discretion of the CHMP. The 
process for assigning the rapporteur/co-rapporteur is 
usually initiated at the CHMP meeting following the 
receipt of a letter of an intention to submit. The sponsor is 
notified of the rapporteur/co-rapporteur once the EMA has 
deemed a submission admissible. 
Product naming 
A sponsor’s name for the drug product should be the same 
in all countries within the EU, except where it violates 
trademark rules. The sponsor should submit the proposed 
name in advance (usually four to six months, and not more 
than 12 months) of the marketing authorization 
application. 
China- 
Economic reformation in China has being ongoing for 
almost three decades, creating opportunities for rapid 
growth in many areas including pharmaceutical industry. 
Drug research and development in China went through a 
revolutionary change during this period as indicated by the 
large number of scientific institutes for drug research, the 
impressive depth of drug research in many therapeutic 
areas and the rapidly increasing number of new drugs. A 
new era of drug research and development is on the 
horizon with the introduction of new scientific 
breakthroughs, such as biomarkers and 
pharmacogenomics. A unique drug evaluation system is 
needed in China not only to keep up with the scientific 
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development in drug research and development but also fit 
into the current overall economic environment in China. 
Standard Procedure - 
Currently, there are five types of drug registration 
application in China: New drug application, generic drug 
application, imported drug application, supplemental 
application and renewal application. For the first three 
types of application, there are two major stages that are 
under regulation in China: application to initiate clinical 
trials (including bioequivalent trials) and application to 
market or import a drug. According to the Drug 
Administration Law, approval by SFDA is required before 
clinical trials can be conducted in China or new drugs can 
be marketed in or imported into China. The detailed 
application procedure and review process for these two 
stages are outlined in the 2007 version of Drug 
Registration Regulations. For supplemental application, 
the review process will depend on the magnitude of change 
in the product and the specific application documents. 
Clinical trials are required if necessary. For renewal 
application, each approved drug should be re-evaluated 
after 5 years and the renewal approval will depend on 
whether the post-marketing data suggest serious drug 
safety issues or not during the last 5 years. Overall, the 
review processes for these applications in CDE are similar 
to those implemented by US FDA .There are review teams 
that are made of reviewers with expertise in different 
disciplines. The review team is responsible for evaluating 
whether the submitted data and documents support the 
safety and efficacy of the new drug as indicated. During 
the review process, reviewers may interact with external 
experts and the drug developers to reduce the uncertainty 
about the drug’s safety and effectiveness based on the 
submitted information. The final decision for approval will 
be based on the risk/benefit balance for a specific 
indication after all the submitted information for the new 
drug is integrated during the drug evaluation process. For 
new molecular entities that are developed for serious or 
life-threatening diseases or diseases for which there is no 
available treatment, there exists fast track evaluation to 
accelerate the evaluation process (Yin, 2006). But based 
on the short history of twenty-five years (from 1984 to 
2009) and the large number of applications  the drug 
evaluation system in China is different from any other 
countries’. It has its own characteristics with the quality 
control of the review, open-minded review, promoting 
research within CDE and integrating the post-marketing 
review. 
India 
The Drug and Cosmetic Act 1940 and Rules 1945 were 
passed by the India's parliament to regulate the import, 
manufacture, distribution and sale of drugs and cosmetics. 
The Central Drugs Standard Control Organization 
(CDSCO), and the office of its leader, the Drugs Controller 
General (India) [DCGI] was established. In 1988, the 
Indian government added Schedule Y to the Drug and 
Cosmetics Rules 1945. Schedule Y provides the guidelines 
and requirements for clinical trials, which was further 
revised in 2005 to bring it at par with internationally 
accepted procedure. The changes includes, establishing 
definitions for Phase I–IV trials and clear responsibilities 
for investigators and sponsors. The clinical trials were 
further divided into two categories in 2006. In one 
category (category A) clinical trials can be conducted in 
other markets with competent and mature regulatory 
systems whereas the remaining ones fall in to another 
category (category B) Other than A. Clinical trials of 
category A (approved in the U.S., Britain, Switzerland, 
Australia, Canada, Germany, South Africa, Japan and 
European Union) are eligible for fast tracking in India, and 
are likely to be approved within eight weeks. The clinical 
trials of category B are under more scrutiny, and approve 
within 16 to 18 weeks. 
An application to conduct clinical trials in India should be 
submitted along with the data of chemistry, manufacturing, 
control and animal studies to DCGI. The date regarding 
the trial protocol, investigator's brochures, and informed 
consent documents should also be attached. 
 A copy of the application must be submitted to the ethical 
committee and the clinical trials are conducted only after 
approval of DCGI and ethical committee. To determine the 
maximum tolerated dose in humans, adverse reactions, etc. 
on healthy human volunteers, Phase I clinical trials are 
conducted. The therapeutic uses and effective dose ranges 
are determined in Phase II trials in 10-12 patients at each 
dose level. The confirmatory trials (Phase III) are 
conducted to generate data regarding the efficacy and 
safety of the drug in ~ 100 patients (in 3-4 centers) to 
confirm efficacy and safety claims. Phase III trials should 
be conducted on a minimum of 500 patients spread across 
10-15 centers, If the new drug substance is not marketed in 
any other country. The new drug registration (using form # 
44 along with full pre-clinical and clinical testing 
information) is applied after the completion of clinical 
trials. The comprehensive information on the marketing 
status of the drug in other countries is also required other 
than the information on safety and efficacy. The 
information regarding the prescription, samples and testing 
protocols, product monograph, labels, and cartons must 
also be submitted. The application can be reviewed in a 
range of about 12-18 months. Figure  represents the new 
drug approval process of India. After the NDA approval, 
when a company is allowed to distribute and market the 
product, it is considered to be in Phase IV trials, in which 
new uses or new populations, long-term effects, etc. are 
explored.
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Table 1: Drug Approval Stages in India 
                                               Clinical Trials 
 Preclinical 
testing 
 Phase I Phase II  
 
Phase III  FDA  Phase IV 
 
Years 
 
3.5 
  
1 
 
  2  
 
 
3 
  
2.5 
 
12  
total 
Additional 
Post 
marketing  
testing 
required 
by FDA 
Test 
Population 
Laboratory 
and animal 
studies 
 
 
File 
IND 
at 
FDA 
20- 80 
Healthy 
volunteer 
100-300 
patient 
volunteers 
1000-3000 
patient 
volunteers 
File 
NDA at 
FDA 
Review 
process / 
Approval 
  
Purpose Assess 
safety and 
biological 
activity 
determine 
safety and 
dosage 
    
Success 
Rate 
5,000 
compounds 
evaluated 
      
            5 enter trials 
    1 
approved 
  
 
Australia- 
The Therapeutic Goods Administration is a 
Commonwealth Government agency that regulates medical 
devices and drugs. Prescription medicines and over-the-
counter medicines which meet Australian standards of 
quality, safety and efficacy are included on the Australian 
Register of Therapeutic Goods. Medicines may be 
registered or listed. Registered products are thoroughly 
evaluated and are  labelled   with an AUST R number. 
 The TGA administers the Therapeutic Goods Act 1989, 
the objects of which include 'a national system of controls 
relating to the quality, safety, efficacy and timely 
availability of therapeutic goods that are used in Australia, 
whether produced in Australia or elsewhere, or exported 
from Australia'. These activities are fully funded by fees 
charged for assessments, annual registrations and 
inspections. 
AUST R products 
Medicines that are registered include: 
 Almost all prescription medicines 
 A number of products, such as vaccines, which 
although not classified in law as needing a 
prescription warrant detailed evaluation 
 Almost all conventional over-the-counter medicines  
 A very small number of complementary medicines 
where the TGA has been satisfied that   pecific claims 
of efficacy in treatment or prevention of a disease are 
supported by adequate evidence. 
Prescription medicines 
The Australian system for the pre-registration evaluation 
of new active substances, as well as such things as new 
routes of administration and the extensions of approved 
uses ('indications') of already marketed products, has 
evolved since it was established in 1963. Most prescription 
medicines in use currently have been evaluated through 
this system. Nowadays an application for registration of a 
new active substance must be supported by extensive 
information about the synthesis of the substance, the 
method of manufacture of the dose forms, studies of its 
pharmacology and toxicology in animals and clinical trials 
in humans demonstrating the efficacy and safety of the 
product in its proposed use. In addition, certification that 
manufacture has complied with Good Manufacturing 
Practice is obligatory.  Registration in Australia does not 
expire. A product remains registered unless there are 
grounds for cancellation or the sponsor ceases marketing. 
A small number of active substances, such as aspirin, were 
supplied in Australia long before any evaluation process 
was in place. Their registration is not reviewed unless a 
safety issue arises or a change in use is proposed. 
Many of the prescription medicines used in Australia are 
versions of the innovator product, usually produced by 
other manufacturers. These generic products are subject to 
the same regulation of manufacture and quality standards. 
However, only evidence that the formulation is 
bioequivalent to the innovator product is required, rather 
than a full demonstration of efficacy and safety.1 
Bioequivalence studies usually involve a comparative 
study of the product in human volunteers, but benchtop 
testing of dissolution may suffice for some products. 
Similar testing in human volunteers is required to support 
the claims of modified-release formulations. 
Over-the-counter medicines 
Nowadays, almost all active substances in non-prescription 
medicines first enter the market as ingredients of 
prescription medicines. To assess whether or not an active 
substance is suitable for use in a non-prescription medicine 
usually requires the substance to have been used for at 
least two years as a prescription medicine. Not all active 
substances make the transition from prescription to over-
the-counter use. The volume of new information to support 
efficacy and safety is usually less, because the registration 
of the over-the-counter product can draw on the 
accumulated experience as a prescription product. New 
over-the-counter products are assessed by the TGA for 
quality, efficacy and safety. The standards for such things 
as quality and circumstances of manufacture are essentially 
the same as those of prescription medicines. 
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AUST L products 
The group of medicines that are listed consists almost 
entirely of complementary medicines. These include herbal 
medicines, most vitamin and mineral supplements, other 
nutritional supplements, traditional medicines such as 
Ayurvedic medicines and traditional Chinese medicines, 
and aromatherapy oils.This category of listed products 
came into effect in 1991 as a means of regulating products 
that seemed by their nature to have a low risk of causing 
adverse effects. Similar requirements for manufacture, 
including certification of Good Manufacturing Practice, 
apply as to AUST R products, but they are not evaluated 
before inclusion in the ARTG. The principal mechanism 
for ensuring that these products are safe is through the 
requirements of the Therapeutic Goods Regulations 1990. 
AUST L medicines must:  
 not contain substances that are prohibited imports, 
come from endangered species or be covered by the 
national regulations which control access to many 
substances (Standard for the Uniform Scheduling of 
Drugs and Poisons) 
 Conform to lists of permitted ingredients (minerals, 
vitamins, declared listable substances). 
 In some instances, there are additional requirements 
such as dose limits, specified label warnings and limits 
on plant parts or methods of preparation. Certain herbs 
are not permitted. 
 The initial approach to regulation of AUST L products 
did not require evidence to support manufacturers' 
claims, provided the products were not for the 
treatment of serious illnesses. 
A concern that multiple and at times improbable claims 
were being made about products led to the introduction in 
April 1999 of a requirement that sponsors of AUST L 
products must hold evidence to substantiate their claims. 
This evidence may be called for and evaluated by the 
TGA, should a concern or complaint arise at any time 
during the life of a product. If the evidence is inadequate, 
the TGA may cancel the listing for the product. A random   
sample of approximately 20% of new listings is assessed in 
detail for compliance with the listing requirements. 
In 2003 an expert committee recommended that sponsors 
of AUST L medicines should submit summaries of the 
evidence they hold to support the efficacy of their 
products, and that the TGA should randomly audit this 
information.3 Where there is evidence to support the 
efficacy of an AUST L medicine in a serious illness, 
registration (AUST R status) can be sought.  
Exemptions 
Medicines (except for gene therapy) that are dispensed or 
extemporaneously compounded for a particular person are 
currently exempt from TGA regulation. Some clinics and 
pharmacists are using this exemption as a means for 
supplying very large numbers of patients with medicines 
made in those pharmacies. On occasions, claims about 
special characteristics such as 'slow release product' are 
made. Such products are not assessed or regulated by the 
TGA. Similar exemptions apply to medicines individually 
dispensed by traditional Chinese medicine and 
homeopathic practitioners.Some other medicines are also 
exempt from the requirement for inclusion in the ARTG. 
Perhaps the most important are homeopathic medicines. 
This exemption from TGA regulation has seen the 
marketing of such purported homeopathic products as 
homeopathic somatropin and homeopathic melatonin. 
Increased TGA regulation of homeopathic products has 
therefore been recommended.3 This might be expected to 
focus on ensuring that such products are formulated with 
regard to homeopathic principles and practices and are 
made in compliance with the same manufacturing 
requirements as conventional medicines.
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